Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SNPX

SNPX - Synaptogenix, Inc. Stock Price, Fair Value and News

$39.48+1.22 (+3.19%)
Market Closed

9/100

SNPX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

9/100

SNPX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$30.46

Target 3M

$34.27

Target 6M

$32.37

SNPX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNPX Price Action

Last 7 days

-4.3%

Last 30 days

11.4%

Last 90 days

425%

Trailing 12 Months

1018.4%

SNPX RSI Chart

SNPX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNPX Valuation

Market Cap

281.4M

Price/Earnings (Trailing)

-10.58

Price/Sales (Trailing)

502.84

EV/EBITDA

-10.53

Price/Free Cashflow

-55.06

SNPX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$30.46

Target 3M

$34.27

Target 6M

$32.37

SNPX Fundamentals

SNPX Revenue

Revenue (TTM)

559.7K

Rev. Growth (Yr)

-85.6%

Rev. Growth (Qtr)

-71.67%

SNPX Earnings

Earnings (TTM)

-26.6M

Earnings Growth (Yr)

31.67%

Earnings Growth (Qtr)

77.6%

SNPX Profitability

EBT Margin

-4752.46%

Return on Equity

-165.58%

Return on Assets

-144.89%

Free Cashflow Yield

-1.82%

SNPX Investor Care

Shares Dilution (1Y)

425.88%

Diluted EPS (TTM)

4.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025994.8K817.1K559.7K0
20241.7M1.6M1.4M1.3M
2023726.8K1.1M1.5M1.6M
202230.6K54.1K192.3K335.0K
20210104.5K55.8K7.1K
2020322.3K266.0K209.6K153.2K
2019000378.7K
Get all data in R, Python etc through our Historical Stock Data APIs

About Synaptogenix, Inc.

SNPX
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
 CEO
 WEBSITEsynaptogen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES5

Synaptogenix, Inc. Frequently Asked Questions

SNPX is the stock ticker symbol of Synaptogenix, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Synaptogenix, Inc. is 281.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SNPX's fair value in chart for subscribers.

The fair value guage provides a quick view whether SNPX is over valued or under valued. Whether Synaptogenix, Inc. is cheap or expensive depends on the assumptions which impact Synaptogenix, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNPX.

As of Wed Jan 28 2026, SNPX's PE ratio (Price to Earnings) is -10.58 and Price to Sales (PS) ratio is 502.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNPX PE ratio will change depending on the future growth rate expectations of investors.